Efficacy of fixed low dose hydroxyurea in Indian children with sickle cell anemia: a single centre experience

Dipti L Jain1, Mohini Apte, Roshan Colah

  • 1Department of Pediatrics, Government Medical College, Nagpur; and * National Institute of Immunohaematology, Mumbai, India. Correspondence to: Dr Dipti Jain,Professor, Department of Pediatrics, Governement Medical College, Nagpur, Maharashtra 440 003, India. drvijayasarathi@gmail.com.

Indian Pediatrics
|June 27, 2013
PubMed

Insights

Fixed low-dose hydroxyurea (HU) effectively improved fetal hemoglobin and reduced clinical events in Indian children with sickle cell anaemia (SCA). The treatment was found to be safe over a two-year follow-up period.

Area of Science:

  • Pediatric Hematology
  • Sickle Cell Disease Research
  • Pharmacological Interventions

Background:

  • Limited data exists on hydroxyurea (HU) efficacy in Indian children with sickle cell anaemia (SCA).
  • Evaluation of fixed low-dose HU is crucial for this specific pediatric population.

Purpose of the Study:

  • To assess the efficacy and safety of a fixed low dose of hydroxyurea (HU).
  • To evaluate hematological and clinical outcomes in Indian children with severe sickle cell anaemia (SCA).

Main Methods:

  • A cohort of 144 children (<18 years) with severe SCA received fixed low-dose HU (10 mg/kg/day).
  • Participants were monitored for two years for hematological and clinical efficacy and safety parameters.
  • Key metrics included fetal hemoglobin (HbF%), total hemoglobin, MCV, vasoocclusive crises, blood transfusions, and hospitalizations.

Main Results:

  • Significant increases in HbF%, total hemoglobin, and mean corpuscular volume were observed.
  • Marked reductions in vasoocclusive crises, blood transfusions, acute chest syndrome, sequestration crises, and hospitalizations occurred.
  • No major adverse events were reported, indicating a favorable safety profile.

Conclusions:

  • Fixed low-dose hydroxyurea (HU) demonstrates significant efficacy in improving hematological markers.
  • HU treatment led to a substantial decrease in clinical complications and hospitalizations in Indian children with SCA.
  • The study confirms that fixed low-dose HU is a safe and effective therapeutic option for pediatric SCA in India.
Abstract

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant01:25

Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant

In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Hemodialysis II: Procedure and Complications01:24

Hemodialysis II: Procedure and Complications

DialyzersA hemodialysis (HD) dialyzer is a plastic cartridge containing thousands of parallel hollow fibers, which serve as semipermeable membranes. These fibers are typically made from cellulose-based or other synthetic materials. During HD, blood is pumped into the top of the cartridge and distributed among these fibers. Simultaneously, dialysis fluid, known as dialysate, is introduced into the bottom of the cartridge, bathing the outside of the fibers. Across the semipermeable membrane,...
Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

Acute Kidney Injury IV: Diagnostic Studies and Prevention

Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
Dosage Regimen: Fixed Dose01:01

Dosage Regimen: Fixed Dose

Fixed-dose regimens are a common approach to administer drugs to achieve and maintain desired levels of the drug in the body. In this dosing strategy, a specific amount of medication is given at regular intervals, often multiple times a day, to ensure a consistent drug concentration in the bloodstream.
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...